A large US claims analysis links out-of-pocket medication costs with adherence and discontinuation patterns among patients ...
Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...
Doctors in Noida have reported a major advance in psoriasis treatment after a young patient saw near-complete clearance of ...
Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...
The clinical-stage biotechnology company is seeking regulatory clearance to begin clinical trials of CYPS317, an allogeneic ...
A new study published in the Journal of American Medical Association showed that psoriasis patients who used antibiotics had ...
In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...
FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...
SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Positive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis Trial ...
Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the two pivotal Phase 3 randomized, ...
Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of more than $200 million in the first nine months of this year, zasocitinib is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback